TY - JOUR
T1 - Correlation Between Verapamil Plasma Concentration and P‐R Prolongation in Essential Hypertension
AU - Zachariah, Prince K.
AU - Shub, Clarence
AU - Sheps, Sheldon G.
AU - Schirger, Alexander
AU - Wolf, Mary K.
AU - Carlson, Christopher A.
PY - 1988/9
Y1 - 1988/9
N2 - Plasma verapamil concentration was correlated with serial electrocardiographic P‐R intervals in patients with essential hypertension receiving immediate‐release (80 to 120 mg three times a day) or sustained‐release (240 mg daily) verapamil. The mean P‐R interval in 22 patients taking placebo and immediate‐release verapamil was 0.18 second. The borderline first‐degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P‐R interval longer than 0.20 second and of those with a P‐R interval of 0.20 second or less were 169 ± 73 ng/mL and 63 ± 8 ng/mL, respectively. Six patients taking sustained‐release verapamil had a maximal mean P‐R interval of 0.19 ± 0.01 second during 24‐hour ambulatory electrocardiographic monitoring. P‐R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P‐R prolongation occurred with oral verapamil therapy, but no patient, regardless of baseline P‐R interval, developed high‐grade atrioventricular block. 1988 American College of Clinical Pharmacology
AB - Plasma verapamil concentration was correlated with serial electrocardiographic P‐R intervals in patients with essential hypertension receiving immediate‐release (80 to 120 mg three times a day) or sustained‐release (240 mg daily) verapamil. The mean P‐R interval in 22 patients taking placebo and immediate‐release verapamil was 0.18 second. The borderline first‐degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P‐R interval longer than 0.20 second and of those with a P‐R interval of 0.20 second or less were 169 ± 73 ng/mL and 63 ± 8 ng/mL, respectively. Six patients taking sustained‐release verapamil had a maximal mean P‐R interval of 0.19 ± 0.01 second during 24‐hour ambulatory electrocardiographic monitoring. P‐R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P‐R prolongation occurred with oral verapamil therapy, but no patient, regardless of baseline P‐R interval, developed high‐grade atrioventricular block. 1988 American College of Clinical Pharmacology
UR - http://www.scopus.com/inward/record.url?scp=0024215025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024215025&partnerID=8YFLogxK
U2 - 10.1002/j.1552-4604.1988.tb03226.x
DO - 10.1002/j.1552-4604.1988.tb03226.x
M3 - Article
C2 - 3230151
AN - SCOPUS:0024215025
SN - 0091-2700
VL - 28
SP - 843
EP - 847
JO - The Journal of Clinical Pharmacology
JF - The Journal of Clinical Pharmacology
IS - 9
ER -